IGF2 and neoplasm: Firstly, aberrant processing of pro‐IGF‐2 in certain tumours leads to increased levels of ‘big’ IGF‐2, which have less efficacy to bind to IGF receptors, thereby potentially lowering the calculated IGF‐2:IGF‐1 ratio.21, 22